AIP
MDGL icon

Ameritas Investment Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

Ameritas Investment Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,400
Closed -$733K – 3272
2026
Q1 		$733K Sell
1,400
-136
-9% -$65K 0.02% 714
2025
Q4 		$894K Sell
1,536
-18
-1% -$9.19K 0.03% 654
2025
Q3 		$713K Sell
1,554
-170
-10% -$63.4K 0.02% 709
2025
Q2 		$522K Sell
1,724
-112
-6% -$33.4K 0.02% 829
2025
Q1 		$608K Sell
1,836
-45
-2% -$14.8K 0.02% 744
2024
Q4 		$580K Buy
1,881
+104
+6% +$29.3K 0.02% 770
2024
Q3 		$377K Buy
1,777
+58
+3% +$14.8K 0.01% 957
2024
Q2 		$482K Buy
1,719
+243
+16% +$57.8K 0.02% 812
2024
Q1 		$394K Sell
1,476
-56
-4% -$13.2K 0.01% 905
2023
Q4 		$354K Buy
1,532
+179
+13% +$31.3K 0.01% 934
2023
Q3 		$198K Buy
1,353
+228
+20% +$42.9K 0.01% 1180
2023
Q2 		$260K Buy
1,125
+135
+14% +$36.6K 0.01% 986
2023
Q1 		$240K Buy
990
+50
+5% +$13.6K 0.01% 992
2022
Q4 		$287K Buy
940
+50
+6% +$4.89K 0.01% 949
2022
Q3 		$57K Hold
890
– – ﹤0.01% 1880
2022
Q2 		$63K Hold
890
– – ﹤0.01% 1838
2022
Q1 		$87K Hold
890
– – ﹤0.01% 1737
2021
Q4 		$75K Hold
890
– – ﹤0.01% 1861
2021
Q3 		$71K Hold
890
– – ﹤0.01% 1915
2021
Q2 		$87K Buy
890
+103
+13% +$12.2K ﹤0.01% 1815
2021
Q1 		$92K Hold
787
– – ﹤0.01% 1725
2020
Q4 		$87K Hold
787
– – ﹤0.01% 1653
2020
Q3 		$93K Hold
787
– – ﹤0.01% 1472
2020
Q2 		$89K Buy
787
+100
+15% +$9.83K ﹤0.01% 1483
2020
Q1 		$46K Hold
687
– – ﹤0.01% 1706
2019
Q4 		$63K Buy
687
+89
+15% +$8.63K ﹤0.01% 1778
2019
Q3 		$52K Hold
598
– – ﹤0.01% 1863
2019
Q2 		$63K Hold
598
– – ﹤0.01% 1785
2019
Q1 		$75K Hold
598
– – ﹤0.01% 1663
2018
Q4 		$67K Hold
598
– – ﹤0.01% 1639
2018
Q3 		$128K Buy
598
+86
+17% +$21.6K 0.01% 1380
2018
Q2 		$143K Buy
512
+157
+44% +$27.6K 0.01% 1292
2018
Q1 		$41K Hold
355
– – ﹤0.01% 2025
2017
Q4 		$33K Hold
355
– – ﹤0.01% 2166
2017
Q3 		$6K Hold
355
– – ﹤0.01% 2894
2017
Q2 		$6K Buy
+355
New +$5.55K ﹤0.01% 2916

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameritas Investment Partners's MDGL Position: Q2 2026 in Review

Ameritas Investment Partners sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2026, closing a stake of 1,400 shares — an estimated $733K sold.

Ameritas Investment Partners first reported a position in MDGL in Q2 2017 and held it in 36 quarters. The position peaked at $894K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Ameritas Investment Partners reported no remaining Madrigal Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Ameritas Investment Partners sold 1,400 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $733K.
  • Ameritas Investment Partners first reported a position in Madrigal Pharmaceuticals in Q2 2017 and held it in 36 quarters.
  • Ameritas Investment Partners's Madrigal Pharmaceuticals position peaked at $894K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.